Puma Biotechnology (PBYI) Assets (2010 - 2026)

Puma Biotechnology's Assets history runs 17 years deep, the most recent figure standing at $192.7 million for Q1 2026.

• Quarterly Assets fell 1.77% year-over-year to $192.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.7 million (down 1.77% YoY) and the FY2025 annual result came in at $216.3 million, up 1.39% from the prior year.
• Assets was $192.7 million for Q1 2026 at Puma Biotechnology, down from $216.3 million in the prior quarter.
• Across five years, Assets topped out at $230.5 million in Q4 2023 and bottomed at $192.7 million in Q1 2026.
• A 5-year average of $206.0 million and a median of $202.9 million in 2025 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets slipped 25.52% — and 2024, when it grew 9.12%.
• Puma Biotechnology's Assets stood at $222.1 million in 2022, then grew by 3.81% to $230.5 million in 2023, then declined by 7.46% to $213.3 million in 2024, then climbed by 1.39% to $216.3 million in 2025, then dropped by 10.91% to $192.7 million in 2026.
• Business Quant data shows PBYI's Assets at $192.7 million in Q1 2026, $216.3 million in Q4 2025, and $202.9 million in Q3 2025.